One multicenter, randomized, open, phase III clinical study on SHR3680 combined with androgen deprived therapy (ADT) versus Bicalutamide combined with ADT in treatment of metastatic hormone-sensitive prostate cancer with high tumor load.
Фаза 3 – широко изпитване преди одобрение
Заболявания:
Metastatic hormone-sensitive prostate cancer with high tumor load
Спонсор: Jiangsu Hengrui Pharmaceuticals Co. Ltd.
Налично на:
БГ
Обобщение
Trial status: Authorised
Time to PSA progression., Time to the next bone related event (including fracture, spinal compression, radiotherapy or surgery for bones)., Time to the start of the next anti-prostate cancer treatment., ORR, Safety endpoint.
rPFS,OS
Описание
Time to PSA progression., Time to the next bone related event (including fracture, spinal compression, radiotherapy or surgery for bones)., Time to the start of the next anti-prostate cancer treatment., ORR, Safety endpoint.
Кой може да участва
Age group: 18-64 years, 65+ years
Gender: Male
Target enrollment: 63 participants
БГ
EN